Welcome to the Health Marketing Collective, where strong leadership meets marketing excellence.

In today’s episode, our host Sara Payne is joined by Andrew Lacy, CEO of Prenuvo, recorded live on the floor of HLTH 2025. Together, they dive into the evolving landscape of preventive healthcare, examining the bold moves required to shift from reactive late-stage disease management to proactive early detection and holistic diagnostics.

Andrew brings his experience as an innovator in healthcare, spearheading Prenuvo’s mission to redefine the annual physical through advanced whole-body imaging and blood biomarkers. Their approach opens the door to detecting life-threatening diseases earlier and helping individuals understand the real impact their lifestyle has on long-term health outcomes.

The conversation explores why the traditional health system is lagging in diagnostics, the uncomfortable truths that must be confronted for meaningful change, and how both messaging and clinic experience play a critical role in overcoming patients' fear and nurturing gratitude after preventive screening. Sara and Andrew also touch on the systemic and economic challenges of proving ROI for preventive innovations, especially with employers and payers, and how data-driven evidence and strategic partnerships can unlock wider adoption.

Thank you for being part of the Health Marketing Collective, where strong leadership meets marketing excellence. The future of healthcare depends on it.

Key Takeaways:

1. A New Model for the Annual Physical: Andrew Lacy describes Prenuvo as the “annual physical of the future,” integrating whole-body imaging and blood biomarkers to proactively identify disease. By offering a more comprehensive view than traditional checkups, Prenuvo aims to close the gaps left by current approaches which often produce false negatives and leave individuals in the dark about their health status.
2. Uncomfortable Truths Behind Early Detection: The episode highlights a critical mindset shift required in healthcare: current cancer screenings cover only about 14% of diagnosed cancers, leaving vast blind spots across organs like the liver, kidneys, and brain—areas rarely screened. Andrew emphasizes that true reform lies in challenging incremental fixes and pushing for large-scale preventive health solutions, even as system inertia resists radical change.
3. Mindset, Messaging & Patient Experience: Fear and anxiety are common reactions to the idea of deep health screening, not just for patients but also physicians. Andrew discusses how Prenuvo addresses this by offering warm, inviting clinic environments and reframing preventive health as a form of empowerment rather than dread. Breaking down these psychological barriers through thoughtful marketing and messaging is essential for shifting public and professional attitudes.
4. Driving Adoption Through Education & Evidence: Change doesn’t happen overnight. Prenuvo’s strategy involves educating physicians—often skeptics themselves—by turning them into advocates after experiencing screenings personally or through their patients. The company is investing in prospective clinical trials to gather the long-term data necessary for convincing payers, employers, and insurance providers to support and cover preventive diagnostics.
5. Navigating Economic Challenges for Preventive Health: One of the episode’s key marketing challenges is proving the ROI for preventive interventions in a system where patients often change jobs (and insurance plans). Andrew shares how partnering with blue-collar employers, who see long-term employee loyalty and higher occupational risks, provides an ideal proving ground for demonstrating impact. This targeted approach lays the groundwork for broader adoption, beginning with high-risk populations and expanding coverage incrementally as evidence builds.

Learn more about Prenuvo at prenuvo.com.